Sagimet Biosciences Inc - Ordinary Shares - Class A

NASDAQ:SGMT

2.52

-0.15 (-5.62%)

7:38:54 PM EDT: $2.65 +0.13 (+5.16%)

Sagimet Biosciences Inc - Ordinary Shares - Class A Stock, NASDAQ:SGMT

155 Bovet Road, Suite 303, San Mateo, California 94402

United States of America

Phone: +1.650.561.8600

Number of Employees: 10

http://www.sagimet.com

Description

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.